Ehsan Malek, MD
Medical Oncology · Buffalo, NYNPI 1205061702
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $644,614 of the $826,148 with a category attached, or 78.0%. It is spread thinly across 16 manufacturers, the largest accounting for just 22.9%. Reporting peaked in 2022 at $168,067 and has fallen 88.9% since, to $18,592 in 2025. Among medical oncology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 667 payments — averaging $1238.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Karyopharm Therapeutics Inc.$189K
- Takeda Pharmaceuticals U.S.A., Inc.$152K
- Amgen$117K
- Johnson & Johnson$110K
- GSK$70K
- E.r. Squibb & Sons, L.L.C.$62K
- plus $125K from 10 others
Across 49 payments — averaging $8100.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$153K
- Genmab U.S., Inc.$68K
- Janssen Research & Development, LLC$45K
- Cumberland Pharmaceuticals, Inc.$40K
- AbbVie$35K
- E.r. Squibb & Sons, L.L.C.$24K
- plus $32K from 2 others
What the payments were for
- Consulting fees$65,3798%
- Speaking & faculty fees$644,61478%
- Travel & lodging$100,47212%
- Food & beverage$15,6832%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Karyopharm Therapeutics Inc. | 101 | $189,256 |
| Takeda Pharmaceuticals U.S.A., Inc. | 114 | $152,322 |
| Amgen | 112 | $116,745 |
| Johnson & Johnson | 151 | $110,159 |
| GSK | 48 | $69,825 |
| E.r. Squibb & Sons, L.L.C. | 44 | $62,437 |
| Sanofi | 34 | $48,660 |
| Adaptive Biotechnologies Corporation | 20 | $33,133 |
| Bristol Myers Squibb | 31 | $27,619 |
| Menarini Silicon Biosystems, Inc. | 3 | $6,435 |
| Legend Biotech USA Inc. | 3 | $3,152 |
| Janssen Scientific Affairs, LLC | 1 | $2,300 |
| Pfizer | 2 | $1,700 |
| Secura Bio, Inc. | 1 | $1,500 |
| Regeneron Healthcare Solutions, Inc. | 1 | $794 |
| Novartis | 1 | $111 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$826,148 in reported general payments places this provider in the 95th percentile of 498 medical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other medical oncology in Buffalo
- Marco DavilaBuffalo$437K
- Saby GeorgeBuffalo$234K
- Nikhil KhushalaniBuffalo$193K
- Francisco Hernandez IlizaliturriBuffalo$158K
- Craig ThompsonNew York$4.8M
- Andrew SeidmanNew York$1.3M
- Maria TheodoulouAlbany$1.1M
- Joshua RichterNew York$971K
- Edward GelmannNew York$944K
- Anthony MatoIthaca$909K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.